

Date Needed By _____ Ship to: ☐ Patient ☐ Office ☐ Other: _____

PATIENT INFORMATION

Name _____

Address _____

City _____ State _____ Zip _____

Phone _____ SS# _____ DOB _____

☐ Male ☐ Female Height _____ Weight _____ Age _____

Allergies _____ ☐ NKDA

INSURANCE INFORMATION

Please attach front and back of all insurance and prescription drug cards

PRESCRIBER INFORMATION

Name _____

NPI _____ State License# _____

Group/Hospital _____

Address _____

City, State, Zip _____

Main Phone _____ Fax _____

Contact Person _____ Phone _____

CLINICAL EVALUATION

DIAGNOSIS

☐ M06.9 Rheumatoid Arthritis
☐ M45.9 Ankylosing Spondylitis
☐ M32.10 Systemic Lupus Erythematosus
☐ L40.8 Psoriasis Moderate to Severe Plaque
☐ L40.50 Psoriatic Arthritis
☐ K50.90 Chron's Disease
☐ M81.0 Osteoporosis
☐ Other _____ DX code _____

Diagnosis Date _____

FORTEO/PROLIA

T-Score _____ Type _____ Date _____

Does patient have latex allergy? ☐ Yes ☐ No

PREVIOUS MEDICATIONS/THERAPIES

Medication	Duration of treatment/Reason for discontinuation
<input type="checkbox"/> Methotrexate	
<input type="checkbox"/>	
<input type="checkbox"/>	
<input type="checkbox"/>	
<input type="checkbox"/>	

LABS

Has TB test been performed?
☐ Yes (please attach results) ☐ No

Lab Date: _____ TB Results: _____

FRACTURE HISTORY

Site	Date

PRESCRIPTION INFORMATION

MEDICATION	DOSAGE & DIRECTIONS	QUANTITY/DURATION	REFILLS
<input type="checkbox"/> ACTEMRA (tocilizumab)	<input type="checkbox"/> 162mg prefilled syringe - Inject subcutaneously: <input type="checkbox"/> ONCE a week <input type="checkbox"/> Every OTHER week <input type="checkbox"/> _____ vial - Infuse _____ mg at _____	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> CIMZIA (certolizumab pegol) <input type="checkbox"/> 200mg x 2 prefilled syringe <input type="checkbox"/> 200mg x 2 LYO powder	<input type="checkbox"/> Starter Kit: Inject 400mg subcutaneously at weeks 0, 2, and 4 <input type="checkbox"/> Maintenance: Inject 400mg subcutaneously ONCE a MONTH <input type="checkbox"/> Maintenance: Inject 200mg subcutaneously ONCE every 2 weeks	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> COSENTYX (secukinumab) <input type="checkbox"/> 150mg syringe <input type="checkbox"/> 150mg pen	<input type="checkbox"/> Psoriatic arthritis induction (optional): 150mg subcutaneously at weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> Psoriatic arthritis maintenance: 150mg subcutaneously every 4 weeks <input type="checkbox"/> Ankylosing spondylitis induction (optional): 150mg subcutaneously at weeks 0, 1, 2, 3, and 4 <input type="checkbox"/> Psoriatic arthritis maintenance: 150mg subcutaneously every 4 weeks <input type="checkbox"/> Other:	<input type="checkbox"/> Enter quantity _____	
<input type="checkbox"/> ENBREL (etanercept) <input type="checkbox"/> 50mg prefilled syringe <input type="checkbox"/> 50mg SureClick	<input type="checkbox"/> Inject 50mg subcutaneously ONCE a week <input type="checkbox"/> Inject 25mg subcutaneously TWICE a week 72-96 hours apart	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> FORTEO (teriparatide rDNA origin)	<input type="checkbox"/> Multi-dose prefilled pen - Inject 20mcg subcutaneously ONCE daily	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> HUMIRA (adalimumab) <input type="checkbox"/> 40mg/0.8ml pen <input type="checkbox"/> 40mg/0.8ml prefilled syringe	<input type="checkbox"/> Inject 40mg subcutaneously every OTHER week <input type="checkbox"/> Inject 40mg subcutaneously ONCE a week	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> ORENCIA (abatacept) <input type="checkbox"/> 125mg prefilled syringe <input type="checkbox"/> 250mg vials	<input type="checkbox"/> Inject 125mg subcutaneously ONCE a week <input type="checkbox"/> Infuse _____ mg at _____	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> OTEZLA (apremilast) <input type="checkbox"/> Starter pack <input type="checkbox"/> 30mg tablets	<input type="checkbox"/> Starter pack: Initial titration over 5 days <input type="checkbox"/> Maintenance: Take 1 tablet by mouth twice daily	<input type="checkbox"/> 1 Starter pack <input type="checkbox"/> 60 tablets	
<input type="checkbox"/> PROLIA (denosumab)	<input type="checkbox"/> 60mg syringe: Inject 60mg subcutaneously once every 6 months	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> REMICADE (infliximab)	<input type="checkbox"/> Infuse _____ mg at _____	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> RITUXAN (rituximab)	<input type="checkbox"/> Infuse _____ mg at _____	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> SIMPONI (golimumab) <input type="checkbox"/> 50mg SmartJect <input type="checkbox"/> ARIA <input type="checkbox"/> PFS	<input type="checkbox"/> Inject 50mg subcutaneously ONCE a MONTH as directed <input type="checkbox"/> Infuse _____ mg at weeks 0 and 4, then every 12 weeks	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> STELARA (ustekinumab) <input type="checkbox"/> 45mg prefilled syringe <input type="checkbox"/> 90mg syringe	<input type="checkbox"/> Inject 45mg on day 0, then week 4, then every 12 weeks <input type="checkbox"/> Inject 90mg subcutaneously ONCE a MONTH as directed	<input type="checkbox"/> 4-Weeks supply	
<input type="checkbox"/> TYMLOS (abaloparatide)	<input type="checkbox"/> Inject 80mcg subcutaneously ONCE daily	<input type="checkbox"/> Enter quantity _____	
<input type="checkbox"/> XELJANZ (tofacitinib citrate)	<input type="checkbox"/> 5mg tablet - Take 1 by mouth TWICE daily	<input type="checkbox"/> 60 tablets	
<input type="checkbox"/> OTHER			

By signing this form and utilizing our services, you are authorizing Echo Care Specialty Pharmacy and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber's Signature _____ ☐ DAW Date _____

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addresses you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.